About Burkitt Lymphoma
Burkitt Lymphoma is one of the rare types of B-cell non-Hodgkin’s lymphoma. It constitutes about 1-2% of all types of non-Hodgkins lymphoma types. It progresses at a very high rate and could be fatal if left untreated during the early stages.
Technavio’s analysts forecast the Global Burkitt Lymphoma Market to grow at a CAGR of 3.07% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the Burkitt lymphoma market. To calculate the market size, the report considers the revenue generated from Burkitt lymphoma market.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Burkitt lymphoma market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Biogen
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Spectrum Pharmaceuticals
Market driver
• Increasing cases of EBV and HIV-1 in patients with Burkitt lymphoma in Africa
• For a full, detailed list, view our report
Market challenge
• High cost of the treatment
• For a full, detailed list, view our report
Market trend
• Heavy investments in R&D for oncology drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: DISEASE OVERVIEW
• Burkitt lymphoma
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE
PART 09: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
• Comparison by drug class
• Biological – Market size and forecast 2017-2022
• Small molecule – Market size and forecast 2017-2022
• Market opportunity by drug class
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Biogen
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Spectrum Pharmaceuticals
PART 17: APPENDIX
• List of abbreviations
PART 18: EXPLORE TECHNAVIO
Exhibit 01: Parent market
Exhibit 02: Global Burkitt lymphoma therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global Burkitt lymphoma therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global Burkitt lymphoma therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials
Exhibit 20: Global Burkitt lymphoma therapeutics market by drug class – Market share 2017-2022 (%)
Exhibit 21: Comparison by drug class
Exhibit 22: Global Burkitt lymphoma biological therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global Burkitt lymphoma biological therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global Burkitt lymphoma small molecule therapeutics market– Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global Burkitt lymphoma small molecule therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by drug class
Exhibit 27: Customer landscape
Exhibit 28: Global Burkitt lymphoma therapeutics market by geography – Market share 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Burkitt lymphoma therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Burkitt lymphoma therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Burkitt lymphoma therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Burkitt lymphoma therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 34: Burkitt lymphoma therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Burkitt lymphoma therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Biogen: Overview
Exhibit 44: Biogen – Business segments
Exhibit 45: Biogen – Organizational developments
Exhibit 46: Biogen – Geographic focus
Exhibit 47: Biogen – Segment focus
Exhibit 48: Biogen – Key offerings
Exhibit 49: Biogen – Key customers
Exhibit 50: F. Hoffmann-La Roche: Overview
Exhibit 51: F. Hoffmann-La Roche – Business segments
Exhibit 52: F. Hoffmann-La Roche – Organizational developments
Exhibit 53: F. Hoffmann-La Roche – Geographic focus
Exhibit 54: F. Hoffmann-La Roche – Segment focus
Exhibit 55: F. Hoffmann-La Roche – Key offerings
Exhibit 56: F. Hoffmann-La Roche – Key customers
Exhibit 57: Merck Sharp & Dohme: Overview
Exhibit 58: Merck Sharp & Dohme – Business segments
Exhibit 59: Merck Sharp & Dohme – Organizational developments
Exhibit 60: Merck Sharp & Dohme – Geographic focus
Exhibit 61: Merck Sharp & Dohme – Segment focus
Exhibit 62: Merck Sharp & Dohme – Key offerings
Exhibit 63: Merck Sharp & Dohme – Key customers
Exhibit 64: Novartis: Overview
Exhibit 65: Novartis – Business segments
Exhibit 66: Novartis – Organizational developments
Exhibit 67: Novartis – Geographic focus
Exhibit 68: Novartis – Segment focus
Exhibit 69: Novartis – Key offerings
Exhibit 70: Novartis – Key customers
Exhibit 71: Spectrum Pharmaceuticals: Overview
Exhibit 72: Spectrum Pharmaceuticals – Business segments
Exhibit 73: Spectrum Pharmaceuticals – Organizational developments
Exhibit 74: Spectrum Pharmaceuticals – Geographic focus
Exhibit 75: Spectrum Pharmaceuticals – Segment focus
Exhibit 76: Spectrum Pharmaceuticals – Key offerings
Exhibit 77: Spectrum Pharmaceuticals – Key customers
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: DISEASE OVERVIEW
• Burkitt lymphoma
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE
PART 09: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
• Comparison by drug class
• Biological – Market size and forecast 2017-2022
• Small molecule – Market size and forecast 2017-2022
• Market opportunity by drug class
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Biogen
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Spectrum Pharmaceuticals
PART 17: APPENDIX
• List of abbreviations
PART 18: EXPLORE TECHNAVIO
Exhibit 01: Parent market
Exhibit 02: Global Burkitt lymphoma therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global Burkitt lymphoma therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global Burkitt lymphoma therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials
Exhibit 20: Global Burkitt lymphoma therapeutics market by drug class – Market share 2017-2022 (%)
Exhibit 21: Comparison by drug class
Exhibit 22: Global Burkitt lymphoma biological therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global Burkitt lymphoma biological therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global Burkitt lymphoma small molecule therapeutics market– Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global Burkitt lymphoma small molecule therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by drug class
Exhibit 27: Customer landscape
Exhibit 28: Global Burkitt lymphoma therapeutics market by geography – Market share 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Burkitt lymphoma therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Burkitt lymphoma therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Burkitt lymphoma therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Burkitt lymphoma therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 34: Burkitt lymphoma therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Burkitt lymphoma therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Biogen: Overview
Exhibit 44: Biogen – Business segments
Exhibit 45: Biogen – Organizational developments
Exhibit 46: Biogen – Geographic focus
Exhibit 47: Biogen – Segment focus
Exhibit 48: Biogen – Key offerings
Exhibit 49: Biogen – Key customers
Exhibit 50: F. Hoffmann-La Roche: Overview
Exhibit 51: F. Hoffmann-La Roche – Business segments
Exhibit 52: F. Hoffmann-La Roche – Organizational developments
Exhibit 53: F. Hoffmann-La Roche – Geographic focus
Exhibit 54: F. Hoffmann-La Roche – Segment focus
Exhibit 55: F. Hoffmann-La Roche – Key offerings
Exhibit 56: F. Hoffmann-La Roche – Key customers
Exhibit 57: Merck Sharp & Dohme: Overview
Exhibit 58: Merck Sharp & Dohme – Business segments
Exhibit 59: Merck Sharp & Dohme – Organizational developments
Exhibit 60: Merck Sharp & Dohme – Geographic focus
Exhibit 61: Merck Sharp & Dohme – Segment focus
Exhibit 62: Merck Sharp & Dohme – Key offerings
Exhibit 63: Merck Sharp & Dohme – Key customers
Exhibit 64: Novartis: Overview
Exhibit 65: Novartis – Business segments
Exhibit 66: Novartis – Organizational developments
Exhibit 67: Novartis – Geographic focus
Exhibit 68: Novartis – Segment focus
Exhibit 69: Novartis – Key offerings
Exhibit 70: Novartis – Key customers
Exhibit 71: Spectrum Pharmaceuticals: Overview
Exhibit 72: Spectrum Pharmaceuticals – Business segments
Exhibit 73: Spectrum Pharmaceuticals – Organizational developments
Exhibit 74: Spectrum Pharmaceuticals – Geographic focus
Exhibit 75: Spectrum Pharmaceuticals – Segment focus
Exhibit 76: Spectrum Pharmaceuticals – Key offerings
Exhibit 77: Spectrum Pharmaceuticals – Key customers
